Carlsmed (NASDAQ:CARL) Stock Price Breaks Above 50-Day Moving Average – What’s Next?

Carlsmed, Inc. (NASDAQ:CARL) shares crossed above its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $14.91 and traded as high as $19.15. Carlsmed shares last traded at $18.60, with a volume of 609,879 shares.

Carlsmed News Roundup

These are some of the CARL news items that stood out recently:

• Positive Sentiment: Carlsmed reported Q3 revenue of $21.6 million, up 65% year over year, and a loss of $0.34 per share—narrower than analysts’ expected $0.42 loss. The company also raised its 2026 revenue forecast to $78 million–$80 million. Carlsmed Q3 results and guidance
• Positive Sentiment: Several firms raised their targets while maintaining Buy ratings: BTIG lifted its target to $26 from $24, Truist to $23 from $20, and Needham to $22 from $17. The revisions signal improved analyst expectations following the quarterly report. Analysts raise Carlsmed forecasts
• Positive Sentiment: Management pointed to new DRG-related tailwinds and product launches planned for Q4 as additional potential support for growth. Carlsmed outlook and launches

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Needham & Company LLC upped their target price on Carlsmed from $17.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday. BTIG Research lifted their price objective on Carlsmed from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday. Truist Financial upped their target price on Carlsmed from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday. Wall Street Zen upgraded Carlsmed from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Carlsmed in a research report on Wednesday, November 4th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Carlsmed has a consensus rating of “Moderate Buy” and a consensus target price of $22.00.

Carlsmed Stock Up 26.4%

The firm has a market cap of $507.78 million, a price-to-earnings ratio of -12.57 and a beta of 1.97. The company has a quick ratio of 8.66, a current ratio of 8.84 and a debt-to-equity ratio of 0.18. The firm has a fifty day moving average price of $14.91 and a 200-day moving average price of $12.54.

Carlsmed (NASDAQ:CARL) last released its earnings results on Tuesday, November 10th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.08. Carlsmed had a negative return on equity of 40.55% and a negative net margin of 55.82%. The firm had revenue of $21.55 million for the quarter. As a group, sell-side analysts forecast that Carlsmed, Inc. will post -1.50 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of CARL. Jupiter Topco LLC acquired a new stake in shares of Carlsmed in the second quarter worth approximately $12,992,000. Janus Henderson Group PLC increased its position in Carlsmed by 7.6% during the first quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company’s stock worth $11,108,000 after purchasing an additional 86,834 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new position in Carlsmed during the second quarter worth approximately $6,200,000. BlackRock Inc. acquired a new position in Carlsmed during the second quarter worth approximately $5,528,000. Finally, Russell Investments Group Ltd. raised its stake in Carlsmed by 85.3% during the third quarter. Russell Investments Group Ltd. now owns 257,805 shares of the company’s stock worth $3,627,000 after purchasing an additional 118,663 shares during the period.

Carlsmed Company Profile

Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. Its technology uses patient-specific planning and implant design to help surgeons plan spinal-fusion procedures. The company’s products include aprevo®, a line of patient-specific interbody implants made using 3D printing. Carlsmed’s platform is designed to use a patient’s imaging and surgical plan to tailor implant geometry and support alignment goals. Founded in 2018 and based in Carlsbad, California, Carlsmed serves the U.S. market.